John Aballi Sells 15,698 Shares of Exagen (NASDAQ:XGN) Stock

Exagen Inc. (NASDAQ:XGN) CEO John Aballi sold 15,698 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $3.62, for a total value of $56,826.76. Following the transaction, the chief executive officer directly owned 687,299 shares of the company’s stock, valued at $2,488,022.38. The trade was a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

John Aballi also recently made the following trade(s):

• On Tuesday, February 24th, John Aballi sold 11,430 shares of Exagen stock. The shares were sold at an average price of $3.61, for a total value of $41,262.30.

Exagen Trading Up 5.5%

XGN stock traded up $0.19 on Wednesday, reaching $3.62. The company’s stock had a trading volume of 292,990 shares, compared to its average volume of 524,230. The business has a fifty day simple moving average of $4.52 and a two-hundred day simple moving average of $7.76. Exagen Inc. has a 12-month low of $2.77 and a 12-month high of $12.23. The firm has a market cap of $82.03 million, a PE ratio of -3.93 and a beta of 1.88. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08.

Analyst Ratings Changes

XGN has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exagen in a report on Wednesday, January 21st. B. Riley Financial reissued a “buy” rating and set a $8.00 price objective (down from $18.00) on shares of Exagen in a research report on Friday, January 30th. BTIG Research dropped their price objective on shares of Exagen from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Finally, TD Cowen decreased their target price on shares of Exagen from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, February 24th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.43.

Hedge Funds Weigh In On Exagen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Balyasny Asset Management L.P. raised its stake in shares of Exagen by 27.1% in the fourth quarter. Balyasny Asset Management L.P. now owns 919,187 shares of the company’s stock worth $5,589,000 after purchasing an additional 195,759 shares during the last quarter. Vanguard Group Inc. raised its position in Exagen by 7.7% in the 3rd quarter. Vanguard Group Inc. now owns 733,824 shares of the company’s stock worth $8,065,000 after buying an additional 52,205 shares during the last quarter. Invesco Ltd. purchased a new stake in shares of Exagen during the 3rd quarter valued at about $7,420,000. Kennedy Capital Management LLC boosted its stake in shares of Exagen by 77.6% in the 3rd quarter. Kennedy Capital Management LLC now owns 551,848 shares of the company’s stock worth $6,065,000 after buying an additional 241,127 shares during the last quarter. Finally, Wexford Capital LP grew its holdings in shares of Exagen by 6.9% in the third quarter. Wexford Capital LP now owns 444,927 shares of the company’s stock worth $4,890,000 after acquiring an additional 28,579 shares during the period. 75.25% of the stock is owned by institutional investors.

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.